Skip to Main content Skip to Navigation

Optimisation des propriétés théranostiques de l’émulsion de chimio-Lipiodol utilisée pour la chimio-embolisation de l'hépatocarcinome.

Abstract : Liver Trans-Arterial Chemo-Embolization (TACE) is recommended for non-resectable, intermediate Hepatocellular carcinoma (HCC). The use of drug delivery platforms during TACE allows slow release of chemotherapy into the tumors’ arterial supply and prolonged exposure of the tumor cells while minimizing systemic exposures. Lipiodol-emulsion is one of the most widely used drug delivery platforms for TACE of HCC. However, the release of chemotherapy occurs very rapidly because Lipiodol-emulsions have poor stability. First, we have demonstrated that high stability (using synthetic surfactant as emulsifier) improves the therapeutic properties of Lipiodol-emulsion in a VX2-tumor rabbit model. A literature review also indicates that Lipiodol-emulsion must be water-in-oil (w/o) for better tumor’ uptakes. Next, we analyzed technical parameters that formulate in-vitro w/o emulsions with better stability without any additional emulsifier. We found that progressive incorporation of chemotherapy in the Lipiodol results in much more predictable w/o type and higher stability and that higher ratio of Lipiodol/chemotherapy is also a critical parameter for stability. Then, we develop a new concept of emulsion for TACE that uses Polylactic-co-glycolic acid (PLGA) nanoparticles (Nps) to stabilize Lipiodol and chemotherapy (Pickering-emulsion). In-vitro analysis demonstrated that Pickering-emulsion is the only drug delivery system (versus Lipiodol-emulsion and drug eluding beads) that allows slow and complete release of various chemotherapies (doxorubicin, irinotecan, oxaliplatin) but also of antibodies (anti-CTLA4), making Pickering-emulsion an universal carrier, not only for TACE but also for trans-arterial immunotherapy. Finally, TACE with oxaliplatin were performed in a VX2-tumor rabbit model to compare in-vivo Pickering-emulsion and Lipiodol-emulsion. Thanks to its slow drug release, Pickering-emulsion significantly decreased the systemic exposure but significantly increased the tumor/liver ratio oxaliplatin exposure.
Document type :
Complete list of metadatas

Cited literature [72 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Friday, January 11, 2019 - 1:01:19 AM
Last modification on : Wednesday, September 16, 2020 - 5:51:30 PM
Long-term archiving on: : Friday, April 12, 2019 - 12:49:28 PM


Version validated by the jury (STAR)


  • HAL Id : tel-01977702, version 1



Frédéric Deschamps. Optimisation des propriétés théranostiques de l’émulsion de chimio-Lipiodol utilisée pour la chimio-embolisation de l'hépatocarcinome.. Biotechnologies. Université Paris Saclay (COmUE), 2018. Français. ⟨NNT : 2018SACLS004⟩. ⟨tel-01977702⟩



Record views


Files downloads